Rebound of clinical disease activity after fingolimod discontinuation? A nationwide cohort study of patients in Denmark
Conclusions
Based on average ARR levels, there was no evidence of clinical rebound after fingolimod discontinuation. In total, 12.5% of patients had clinical rebound. Only 3.6%, however, had clinical rebound without disease activity before discontinuation. Disease activity before discontinuation, female sex and younger age were statistically significantly associated with a higher relapse risk after discontinuation.
Source: Journal of Neurology, Neurosurgery and Psychiatry - Category: Neurosurgery Authors: Framke, E., Pontieri, L., Bramow, S., Sellebjerg, F., Magyari, M. Tags: Multiple sclerosis Source Type: research
More News: Brain | Denmark Health | Gilenya | Multiple Sclerosis | Neurology | Neurosurgery | Psychiatry | Statistics | Study